TY - CHAP
T1 - Mesenchymal stem cells in hematopoietic stem cell transplantation
AU - Hematti, Peiman
AU - Kim, Jaehyup
AU - Battiwalla, Minoo
N1 - Funding Information:
Peiman Hematti is recipient of NIH/NHLBI HL081076 K08 award. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Publisher Copyright:
© 2012 Springer Science+Business Media B.V. All rights reserved.
PY - 2014/4/1
Y1 - 2014/4/1
N2 - Hematopoietic stem cell (HSC) transplantation, the only form of stem cell therapy in routine clinical practice, provides a curative option for treatment of a wide variety of malignant and non-malignant disorders. However, this potentially life-saving procedure is often associated with significant morbidity and mortality mainly due to graft versus host disease (GVHD). Mesenchymal stem cells (MSCs) are another type of stem cells present in bone marrow. These cells not only provide the supportive microenvironmental niche for hematopoietic stem cells but are also capable of differentiating into various cell types of mesenchymal origin, such as bone, fat, and cartilage. In vitro and in vivo data suggest that MSCs have low inherent immunogenicity, and modulate immunological responses through interactions with a wide range of innate and adaptive immune cells. MSCs participate in tissue regenerative processes through their diverse biological properties such as paracrine effects through growth factor and cytokine secretion. MSCs derived from bone marrow have been investigated extensively in the context of HSC transplantation, for promotion of engraftment, prevention of GVHD or treatment of GVHD or other complications associated with transplantation. Clinical studies of use of MSCs in HSC transplantation have paved the way for use of MSCs in a wide variety of other clinical indications.
AB - Hematopoietic stem cell (HSC) transplantation, the only form of stem cell therapy in routine clinical practice, provides a curative option for treatment of a wide variety of malignant and non-malignant disorders. However, this potentially life-saving procedure is often associated with significant morbidity and mortality mainly due to graft versus host disease (GVHD). Mesenchymal stem cells (MSCs) are another type of stem cells present in bone marrow. These cells not only provide the supportive microenvironmental niche for hematopoietic stem cells but are also capable of differentiating into various cell types of mesenchymal origin, such as bone, fat, and cartilage. In vitro and in vivo data suggest that MSCs have low inherent immunogenicity, and modulate immunological responses through interactions with a wide range of innate and adaptive immune cells. MSCs participate in tissue regenerative processes through their diverse biological properties such as paracrine effects through growth factor and cytokine secretion. MSCs derived from bone marrow have been investigated extensively in the context of HSC transplantation, for promotion of engraftment, prevention of GVHD or treatment of GVHD or other complications associated with transplantation. Clinical studies of use of MSCs in HSC transplantation have paved the way for use of MSCs in a wide variety of other clinical indications.
KW - Bone marrow transplant
KW - Graft versus host disease
KW - Hematopoietic stem cells
KW - Mesenchymal stem cells
UR - http://www.scopus.com/inward/record.url?scp=84931454685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931454685&partnerID=8YFLogxK
U2 - 10.1007/978-94-007-2801-1_5
DO - 10.1007/978-94-007-2801-1_5
M3 - Chapter
AN - SCOPUS:84931454685
SN - 940072800X
SN - 9789400728004
SP - 101
EP - 115
BT - Stem Cells and Human Diseases
PB - Springer Netherlands
ER -